Stephen Hull has over 25 years of experience in health policy and medical product strategy, for medical devices, diagnostics, pharmaceuticals and biotech products. He is Principal and Founder of Hull Associates, a specialized global reimbursement strategy firm focused on medical device and diagnostic technologies.
With 25 seasoned partners worldwide, his firm routinely assists in the development and execution of comprehensive strategies for product launch and reimbursement in major global markets.
Prior to forming Hull Associates, he served as Sr. Vice President for Global Reimbursement at AdvaMed, in Washington, D.C., the leading U.S.-based medical technology trade association. In that capacity, he worked with every major medical device company in the industry for common reimbursement policy issues in all major therapeutic areas.
His work at AdvaMed included management of hospital inpatient reimbursement issues and design of legislative strategies for the Medicare Modernization Act - which included the establishment of a supplemental new technology Medicare payment in the hospital setting.
Internationally, he designed and launched numerous joint advocacy campaigns, with a primary focus on reimbursement issues, working with sister associations in the major overseas markets.
Before his trade association work, Mr. Hull was a Principal at Covance Health Economics and Outcomes Services, where he executed numerous private and public payor reimbursement and market strategies for medical device, pharmaceutical and biotech products, from nephrology, cardiology and oncology, to treatments for obesity and ophthalmic indications.
Mr. Hull has served in the past as chairman of the Medical Devices Council for the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) and is a frequent speaker at industry seminars on reimbursement issues internationally. He has an advanced degree in health policy from the Johns Hopkins Bloomberg School of Public Health, and a